CH618091A5 - Method for the attenuation of virulent feline rhinotracheitis virus and use of this virus for the production of a vaccine - Google Patents
Method for the attenuation of virulent feline rhinotracheitis virus and use of this virus for the production of a vaccine Download PDFInfo
- Publication number
- CH618091A5 CH618091A5 CH380275A CH380275A CH618091A5 CH 618091 A5 CH618091 A5 CH 618091A5 CH 380275 A CH380275 A CH 380275A CH 380275 A CH380275 A CH 380275A CH 618091 A5 CH618091 A5 CH 618091A5
- Authority
- CH
- Switzerland
- Prior art keywords
- virus
- cat
- cats
- fvr
- vaccine
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 115
- 229960005486 vaccine Drugs 0.000 title claims description 42
- 206010051497 Rhinotracheitis Diseases 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 241000282324 Felis Species 0.000 title description 6
- 241000282326 Felis catus Species 0.000 claims description 112
- 230000002238 attenuated effect Effects 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 239000002054 inoculum Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 description 34
- 238000002255 vaccination Methods 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 11
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000984690 Catherpes Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- -1 other non-toxic Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45434574A | 1974-03-25 | 1974-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH618091A5 true CH618091A5 (en) | 1980-07-15 |
Family
ID=23804244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH380275A CH618091A5 (en) | 1974-03-25 | 1975-03-25 | Method for the attenuation of virulent feline rhinotracheitis virus and use of this virus for the production of a vaccine |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS50154415A (cs) |
| AT (1) | AT340583B (cs) |
| AU (1) | AU502636B2 (cs) |
| BE (1) | BE827157A (cs) |
| CA (1) | CA1058074A (cs) |
| CH (1) | CH618091A5 (cs) |
| DE (1) | DE2512903A1 (cs) |
| ES (1) | ES436028A1 (cs) |
| FR (1) | FR2265405B1 (cs) |
| GB (1) | GB1462545A (cs) |
| NL (1) | NL7503499A (cs) |
| ZA (1) | ZA751854B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287178A (en) * | 1974-03-25 | 1981-09-01 | Pitman-Moore, Inc. | Feline rhinotracheitis vaccine and production and use thereof |
| DE2544510A1 (de) * | 1975-10-04 | 1977-04-14 | Philips Nv | Virales rhinotracheitisvakzin fuer das katzengeschlecht und verfahren zu dessen herstellung |
| FR2327799A1 (fr) * | 1975-10-17 | 1977-05-13 | Philips Nv | Vaccin contre la rhinotracheite virale des felides et procede pour le preparer |
| US4031204A (en) * | 1976-03-30 | 1977-06-21 | Norden Laboratories, Inc. | Feline viral rhinotracheitis vaccine and combination feline viral rhinotracheitis-calicivirus vaccine prepared therefrom |
| US4303644A (en) * | 1979-10-16 | 1981-12-01 | Norden Laboratories, Inc. | Feline infectious peritonitis virus vaccines |
| JPS60196187A (ja) * | 1984-03-16 | 1985-10-04 | Biseibutsu Kagaku Kenkyusho:Kk | 牛のｒｓウイルス弱毒株 |
-
1975
- 1975-03-13 CA CA221,970A patent/CA1058074A/en not_active Expired
- 1975-03-21 AT AT219075A patent/AT340583B/de active
- 1975-03-24 ZA ZA00751854A patent/ZA751854B/xx unknown
- 1975-03-24 NL NL7503499A patent/NL7503499A/xx not_active Application Discontinuation
- 1975-03-24 JP JP50034594A patent/JPS50154415A/ja active Pending
- 1975-03-24 DE DE19752512903 patent/DE2512903A1/de not_active Withdrawn
- 1975-03-24 GB GB1220775A patent/GB1462545A/en not_active Expired
- 1975-03-24 AU AU79446/75A patent/AU502636B2/en not_active Expired
- 1975-03-24 FR FR7509162A patent/FR2265405B1/fr not_active Expired
- 1975-03-25 CH CH380275A patent/CH618091A5/de not_active IP Right Cessation
- 1975-03-25 ES ES436028A patent/ES436028A1/es not_active Expired
- 1975-03-25 BE BE154744A patent/BE827157A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES436028A1 (es) | 1978-06-01 |
| FR2265405A1 (cs) | 1975-10-24 |
| DE2512903A1 (de) | 1975-10-02 |
| JPS50154415A (cs) | 1975-12-12 |
| CA1058074A (en) | 1979-07-10 |
| GB1462545A (en) | 1977-01-26 |
| BE827157A (fr) | 1975-09-25 |
| AU502636B2 (en) | 1979-08-02 |
| NL7503499A (nl) | 1975-09-29 |
| AU7944675A (en) | 1976-09-30 |
| FR2265405B1 (cs) | 1978-07-28 |
| AT340583B (de) | 1977-12-27 |
| ZA751854B (en) | 1976-10-27 |
| ATA219075A (de) | 1977-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69426051T2 (de) | Impfstoff für Geflügel | |
| DE3882599T2 (de) | Hundecoronavirus-Impfstoff. | |
| DE2516274C2 (de) | Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes | |
| US3937812A (en) | Feline calicivirus vaccine and production thereof | |
| CH622702A5 (cs) | ||
| DE2713371C2 (cs) | ||
| DE2708668A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE69216732T2 (de) | Impfstoff gegen den Geflügelanämieerreger | |
| DE60226218T2 (de) | Impfstoff gegen pferdeherpesvirus | |
| DE2717919A1 (de) | Verfahren zur herstellung eines pferde-rhinopneumonievakzins und durch dieses verfahren hergestelltes vakzin | |
| DE2463143C2 (de) | Polyvalente Rindervirus-Lebendimpfstoffe | |
| DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
| DE2362067C2 (de) | Temperaturempfindliche, nicht-pathogene, infektiöse Rinder-Rhinotracheitis-Virusstämme, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Lebendimpfstoffen | |
| DE3853736T2 (de) | Staupevirus-Impfstoff. | |
| DE69835424T2 (de) | Boviner atmungs- und darmcoronavirus als impfstoff | |
| CH618091A5 (en) | Method for the attenuation of virulent feline rhinotracheitis virus and use of this virus for the production of a vaccine | |
| DE2803240A1 (de) | Tollwut-impfstoff | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| CH616959A5 (cs) | ||
| DE2739439C2 (cs) | ||
| DE2415353A1 (de) | Verfahren zur herstellung von temperaturempfindlichen, nicht pathogenen mutanten von herpes simplex typ 2-viren und ihre verwendung zur herstellung von vaccinen | |
| DE69014974T2 (de) | Impfstoff gegen Hundecoronavirus. | |
| US4287178A (en) | Feline rhinotracheitis vaccine and production and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |